title: [Effectiveness of adjuvant chemotherapy in patient with early stages of non-small cell lung cancer depending on proliferation index of tumor].
abstract: Adjuvant chemotherapy is a debatable question in patients with early stages of non-small cell lung cancer (NSCLC). Prognostic/predictive markers should be used for individualizing prescription of adjuvant chemotherapy. The aim of our study was to investigation effectiveness adjuvant chemotherapy in patients with early stages of NSCLC due to proliferation index of tumor. We included in study 254 patients with I-II stages of NSCLC that conducted treatment in department of thoracic surgery Zaporozhye regional clinical oncology center since June 2008 to December 2012. Expression Ki-67, proliferation marker, measured in 95 patients that used adjuvant chemotherapy and in 122 patients with out additional treatment. Measuring of proliferation index was don by next method: 0-5% immunopositive cells--0 point, 6-25%--1 point, 26-50%--2 point, 51-75%-- 3 point, 76-100%--4 point. High expression was > or = 2 points.
  
  
  RESULTS
  Mean of proliferation index in patients with early stages of NSCLC was 37.6% (95% CI, 33.8-41.5%). Median of survival in patients with II stage of NSCLC was 39.7 month if patients conducted adjuvant chemotherapy and 21.4 month with out treatment. It was tendencies increasing survival in patients with II stage of NSCLC after adjuvant chemotherapy, but it was not statistically significant (P = 0.16). Survival patients with high proliferation index was 10.5 month--75 percentile, 18 month--median, 29.9 month--25 percentile. In patients after adjuvant chemotherapy 75 percentile of survival was 34.4 month, median of survival not complete. Survival differences of two group were statistically significant (P < 0.0001). Thus individualization of prescription adjuvant chemotherapy in patient with early stages of NSCLC helps improves results of treatment and avoid unreasonable toxic therapy.
authors.forename: A P
authors.initials: AP
authors.lastname: Kolesnik
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D049109:Cell Proliferation / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D019394:Ki-67 Antigen / Q000096:biosynthesis; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011013:Pneumonectomy; D057285:Precision Medicine
chemical_list: D019394:Ki-67 Antigen; D005047:Etoposide; D002945:Cisplatin